A Review on the Application of Quality by Design Methodology in the Formulation, Development, and Evaluation of Fixed-Dose Combination Tablets
Keywords:
Fixed-dose; Quality by Design; Tablets; Design space; Critical quality attributes.Abstract
Quality by Design (QbD) is a systematic approach used to develop, produce, and control high-quality products. The review article aims to provide a concise overview of the QbD approach employed in the formulation, development, and evaluation of Fixed-Dose Combination (FDC) tablets. This will buttress on the essence of the usage of this approach by pharmaceutical companies and healthcare providers to plan and achieve desired products for effective treatment and meet patients’ needs. In view of this, the review paper highlights the general concepts of QbD and discusses some approaches that are employed to formulate fixed-dose combination/bilayer tablets. The current review also highlights some challenges that might impede the patronage of QbD approach. It is established that the utilization of QbD methodology has proven to have impacted positively and helped in the optimization of the quality of fixed- dose combination/bilayer tablets. QbD is a regulatory requirement for product development in all regulated markets, and its implementation leads to an improvement in product safety, quality, and patient compliance. Despite the challenges associated with its implementation, the benefits are numerous, and it is an essential tool for producing high-quality pharmaceutical products.
References
C. H. Pérez-Beltrán, A. M. Jiménez-Carvelo, A. Torrente-López, N. A. Navas, L. Cuadros-Rodríguez (2023) QbD/PAT-State of the Art of Multivariate Methodologies in Food and Food-Related Biotech Industries. 15(1), 24–40. https://doi.org/10.1007/S12393-022-09324-0
M. Javaid, A. Haleem, R. Pratap Singh, R. Suman (2021) Significance of Quality 4.0 towards comprehensive enhancement in manufacturing sector. 2, 100109. https://doi.org/10.1016/J.SINTL.2021.100109
J. N. Sangshetti, M. Deshpande, Z. Zaheer, D. B. Shinde, R. Arote (2017) Quality by design approach: Regulatory need. 10, S3412–S3425. https://doi.org/10.1016/j.arabjc.2014.01.025
J. P. ter Horst, S. L. Turimella, F. Metsers, A. Zwiers (2021) Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019. 55(3), 583–590. https://doi.org/10.1007/s43441-020-00254-9
R. Dahima, A. Gupta, D. Rathore (2016) Quality by Design (QbD) Approach for Formulation Development of Hydralazine Hydrochloride Tablets. 8(5), 336-341. http://www.jocpr.com
J. Liker (2021) Toyota Way: 14 Management Principles from the World's Greatest Manufacturer. https://www.access-engineeringlibrary.com/content/book/9781260468519
International Conference on Harmonisation (2005) ICH Guideline Q9 on Quality Risk Management. 44(1), 1-20.
U. Kanwal, et al. (2021) Fixed dose single tablet formulation with differential release of amlodipine besylate and simvastatin and its pharmacokinetic profile: QbD and risk assessment approach. 15, 2193-2210. https://doi.org/10.2147/DDDT.S240506
V. Kushwaha, P. Agrawal, T. Azmi, V. Shukla (2022) FIXED DOSE COMBINATION-RATIONALE, USES, ADVANTAGES. 11(13), 628-638. https://doi.org/10.20959/wjpr202213-25618
D. W. Kim, K. Y. Weon (2021) Pharmaceutical application and development of fixed-dose combination: dosage form review. 51(5), 555–570. https://doi.org/10.1007/S40005-021-00543-X
T. Verch, et al. (2022) Analytical Quality by Design, Life Cycle Management, and Method Control. 24(1), 1–21. https://doi.org/10.1208/S12248-022-00685-2/FIGURE
N. S. Arden, A. C. Fisher, K. Tyner, L. X. Yu, S. L. Lee, M. Kopcha (2021) Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. 602, 120554. https://doi.org/10.1016/J.IJPHARM.2021.120554
V. Mishra, S. Thakur, A. Patil, A. Shukla (2018) Quality by design (QbD) approaches in current pharmaceutical set-up. 15(8), 737–758. https://doi.org/10.1080/17425247.2018.1504768
L. Zhang, S. Mao (2017) Application of quality by design in the current drug development. 12(1), 1–8. https://doi.org/10.1016/j.ajps.2016.07.006
B. Jayagopal, O. Pharma, M. Shivashankar (2017) Analytical Quality by Design – A Legitimate Paradigm for Pharmaceutical Analytical Quality by Design – A Legitimate Paradigm for Pharmaceutical Analytical Method Development.
T. Waghule, N. Dabholkar, S. Gorantla, V. K. Rapalli, R. N. Saha, G. Singhvi (2021) Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach. 141, 111940. https://doi.org/10.1016/J.BIOPHA.2021.111940
M. S. Gupta, T. P. Kumar, D. V. Gowda, J. M. Rosenholm (2021) Orodispersible films: Conception to quality by design. 178, 113983. https://doi.org/10.1016/J.ADDR.2021.113983
M. S. Hasnain (2021) Pharmaceutical product development: A quality by design (QbD) approach. 131–146. https://doi.org/10.1016/B978-0-12-820043-8.00017-7
E. J. Kim, J. H. Kim, M. S. Kim, S. H. Jeong, D. H. Choi (2021) Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification. 13(6), 919. https://doi.org/10.3390/PHARMACEUTICS13060919
S. S. Mane, S. S. Kasture, P. Y. Suryawanshi (2022) Emerging Trends and Novel Approaches of Quality by Design. 10(4), 444-454.
A. Dispas, H. T. Avohou, P. Lebrun, P. Hubert, C. Hubert (2018) Quality by Design’s approach for the analysis of impurities in pharmaceutical drug products and drug substances. 101, 24-33. https://doi.org/10.1016/J.TRAC.2017.10.028
H. Bhatia, E. Read, C. Agarabi, K. Brorson, S. Lute (2016) A Design Space Exploration for Control of Critical Quality Attributes of mAb 1.
M. Skotnicki, et al. (2021) Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy. 13(1), 118. https://doi.org/10.3390/PHARMACEUTICS13010118
F. Mahfoud, et al. (2023) Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. 112(2), 197–202. https://doi.org/10.1007/S00392-022-01993-5
D. Desai, J. Wang, H. Wen, X. Li, P. Timmins (2012) Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. 1–12. https://doi.org/10.3109/10837450.2012.660699
M. H. Chun, J. Y. Kim, E. S. Park, D. H. Choi (2021) Development of a robust control strategy for fixed-dose combination bilayer tablets with integrated quality by design, statistical, and process analytical technology approach. 13(9). https://doi.org/10.3390/pharmaceutics13091443
D. H. Won, H. Park, E. S. Ha, H. H. Kim, S. W. Jang, M. S. Kim (2021) Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). 605, 120838. https://doi.org/10.1016/J.IJPHARM.2021.120838
A. R. Lee, S. Y. Kwon, D. H. Choi, E. S. Park (2017) Quality by Design (QbD) approach to optimize the formulation of a bilayer combination tablet (Telmiduou00ae) manufactured via high shear wet granulation. 534(1-2), 144-158.
P. Prajapati, A. Gami, S. Shah (2020) Analytical quality risk management and DoE based development of robust chromatographic method for simultaneous estimation of tizanidine hydrochloride and nimesulide in their combined pharmaceutical dosage forms. 2(2), 1-12.
P. Prajapati, A. Patel, S. Shah (2022) Application of DoE-Based Analytical QRM to Development of the Multipurpose RP-HPLC Method for Estimation of Multiple FDC Products of Telmisartan Using Enhanced AQbD Approach. 60(6), 525-537.
P. B. Prajapati, K. Radadiya, S. A. Shah (2022) Quality Risk Management Based: Analytical Quality by Design Approach to Eco-Friendly and Versatile Chromatography Method for Simultaneous Estimation of Multiple Fixed-Dose-Combination Products of Anti-Diabetic Drugs. 17(1), 111%E2%80%93128.
D. M. Zagalo, J. Sousa, S. Sim%C3%B5es (2022) Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation. 178, 1%E2%80%9324. https://doi.org/10.1016/J.EJPB.2022.07.014
R. Kumar, A. Mittal, M. P. Kulkarni (2022) Quality by Design in Pharmaceutical Development. 99-127.
B. S. Laxman, V. Shankar, S. Siddheshwar (2022) QUALITY BY DESIGN BASED APPROACH FOR ANALYTICAL METHOD VALIDATION. 11(2), 273%E2%80%93286.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.
